CDSCO panel tells Glenmark to submit complete clinical trial report on antidiabetic FDC Drug

Published On 2022-09-24 12:13 GMT   |   Update On 2022-09-24 12:13 GMT

In response to drug major Glenmark proposal to manufacture and market the antidiabetic fixed dose combination Lobeglitazone Sulphate 0.5/0.5mg plus Metformin HCL 500/1000mg ER tablets, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended Glenmark to submit the complete clinical trial report.

This came after the drug maker Glenmark presented their proposal for manufacturing and marketing of Lobeglitazone Sulphate 0.5/0.5mg plus Metformin HCL 500/1000mg ER tablets along with safety efficacy and safety data.

For more details, check out the link given below:

Submit Complete CT Report :CDSCO Tells Glenmark On Antidiabetic FDC Drug


Full View
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News